Skip to main content
Premium Trial:

Request an Annual Quote

Christopher Becker, William Leschensky, Dennis Harris, Paul Bunn, Gail Eckhardt, Eric Rowinsky, Daniel Von Hoff, James Beery


SurroMed has promoted Christopher Becker and William Leschensky to vice president of chemistry and president of intellectual property, respectively.

Becker joined SurroMed as director of chemistry in 2001, after serving as senior director of proteomic technology at Thermo Electron, and previously, as a staff scientist at SRI. He received his PhD in chemistry at UC Berkeley. Leschensky has been director of intellectual property at SurroMed since 2000, and has also been associate general counsel. Before joining SurroMed, he was an associate at the law firm Fish & Neave. He received his MD from the University of Illinois and a law degree from Harvard Law School.

Serologicals has appointed Dennis Harris as chief scientific officer, vice president of research and development, and vice president of business development. He will also serve on the executive operating committee and as a corporate officer.

Harris, 47, comes to Serologicals from Vitra Biosciences. He has also worked for Amersham International, Molecular Dynamics, Amersham Pharmacia Biotech, and Aclara Biosciences. He earned BS and PhD degrees in biochemistry at the University of Sussex, UK.

NaPro Biotherapeutics

has formed a new oncology scientific advisory board. It has named as chairman Paul Bunn, and as members Gail Eckhardt, Eric Rowinsky, and Daniel Von Hoff.

Bunn is the director of the University of Colorado Cancer Center, in Boulder, and previously served as president of the American Society of Clinical Oncology and chairman of the US Food and Drug Administration’s Oncology Drugs Advisory Committee. Bunn received his MD from Cornell University Medical College.

Eckhardt is a professor of medicine and the director of the developmental therapeutics and GI malignancies programs at the University of Colorado Health Science Center in Denver. She has previously served as associate director of clinical research, cancer therapy and the research center at the Institute for Drug Development in San Antonio, Texas. She received an MD from the University of Texas Medical Branch in Galveston.

Rowinsky is director of the Institute for Drug Development, Cancer Therapy and Research Center and clinical professor of medicine at the University of Texas Health Science Center at San Antonio, NaPro said.

Von Hoff is professor of medicine, pathology, molecular and cellular biology and the director of the Arizona Health Sciences Center cancer therapeutics program. He is also director of translational research at the Translational Genomics Research Institute, chief scientific officer for US Oncology, and a founder of ILEX Oncology. Von Hoff received his MD from Columbia University.

NaPro, of Boulder, Colo., is seeking diagnostic and therapeutic applications for its gene-editing technology in cancer.

Decode Genetics has appointed James Beery to its board of directors. Beery is senior of counsel in the London office of Covington & Burling, an international law firm. He comes to Decode’s board from GlaxoSmithKline, where he was senior vice president and general counsel. Beery holds a BA from Harvard College and a JD from Stanford Law School.


Filed under

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.